- Home
- AUTL vs ALDX Comparison
AUTL vs ALDX Comparison
Compare AUTL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- ALDX
- Stock Information
- Founded
- AUTL 2014
- ALDX 2004
- Country
- AUTL United Kingdom
- ALDX United States
- Employees
- AUTL N/A
- ALDX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- ALDX Health Care
- Exchange
- AUTL Nasdaq
- ALDX Nasdaq
- Market Cap
- AUTL 360.6M
- ALDX 133.7M
- IPO Year
- AUTL 2018
- ALDX 2014
- Fundamental
- Price
- AUTL $1.32
- ALDX $2.19
- Analyst Decision
- AUTL Strong Buy
- ALDX Strong Buy
- Analyst Count
- AUTL 5
- ALDX 2
- Target Price
- AUTL $9.32
- ALDX $9.50
- AVG Volume (30 Days)
- AUTL 2.4M
- ALDX 1.5M
- Earning Date
- AUTL 05-08-2025
- ALDX 05-20-2025
- Dividend Yield
- AUTL N/A
- ALDX N/A
- EPS Growth
- AUTL N/A
- ALDX N/A
- EPS
- AUTL N/A
- ALDX N/A
- Revenue
- AUTL $9,011,000.00
- ALDX N/A
- Revenue This Year
- AUTL $277.74
- ALDX N/A
- Revenue Next Year
- AUTL $221.89
- ALDX N/A
- P/E Ratio
- AUTL N/A
- ALDX N/A
- Revenue Growth
- AUTL N/A
- ALDX N/A
- 52 Week Low
- AUTL $1.11
- ALDX $1.14
- 52 Week High
- AUTL $5.00
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- AUTL 45.63
- ALDX 36.53
- Support Level
- AUTL $1.15
- ALDX $1.90
- Resistance Level
- AUTL $1.44
- ALDX $2.89
- Average True Range (ATR)
- AUTL 0.14
- ALDX 0.22
- MACD
- AUTL 0.01
- ALDX 0.09
- Stochastic Oscillator
- AUTL 29.82
- ALDX 33.46
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.